Back
74· Active
Markets4h 52m ago
Dyadic International highlights increasing interest in its C1 protein production platform due to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and growing commercial adoption across various markets.
Archive Window: 7 Days Left
Jupiter, Fla.
Who
Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions ("Dyadic"), Mark A. Emalfarb, Scripps Research, CEPI, Fondazione Biotecnopolo di Siena, European Vaccines Hub, Proliant Health & Biologicals, Fermbox Bio, IBT Bioservices, Inzymes
What
Dyadic International highlights increasing interest in its C1 protein production platform due to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and growing commercial adoption across various markets.
When
Mon, 15 Jun 2026 11:28:03 GMT · 4h 52m ago
Where
Jupiter, Fla. ·
Why
The Bundibugyo Ebola virus outbreak has intensified global infectious disease preparedness efforts, bringing renewed attention to the need for rapid, scalable vaccine and antibody manufacturing.
The Frontline Impact
How this affects you
The increased focus on Dyadic's C1 platform for rapid and scalable biomanufacturing could accelerate the development of vaccines and antibodies during infectious disease outbreaks, potentially improving global health preparedness and response times, while also expanding commercial applications across life sciences, food, nutrition, and industrial markets.
Story chain
3 events in this thread- Currently Reading4h 52m agoDyadic International highlights increasing interest in its C1 protein production platform due to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and growing commercial adoption across various markets.
- Markets4h 52m agoDyadic is highlighting increasing interest in its C1 protein production platform due to global infectious disease preparedness efforts responding to an ongoing Bundibugyo Ebola virus (BDBV) outbreak and expanding commercial adoption.Open article
- Markets4h 52m agoDyadic's C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization across life sciences, food, nutrition and industrial markets.Open article